KraneShares MSCI All China Health Care Index ETF (KURE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
KraneShares MSCI All China Health Care Index ETF (KURE) trades at $19.34 with AI Score 44/100 (Grade C). KraneShares MSCI All China Health Care Index ETF (KURE) aims to replicate the performance of Chinese… Market cap: $111M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for KURE: KURE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KURE against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KURE: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
KraneShares MSCI All China Health Care Index ETF (KURE) Financial Services Profile
KraneShares MSCI All China Health Care Index ETF (KURE) provides targeted exposure to the Chinese healthcare sector, tracking an index of free float adjusted market capitalization weighted companies. With a beta of 0.59 and assets under management of $0.08 billion, KURE offers investors a focused investment vehicle within the Chinese equity market.
What Is the Investment Thesis for KURE?
KURE presents a focused investment opportunity in the Chinese healthcare sector, driven by the increasing demand for healthcare services in China. The fund's strategy of mirroring the MSCI All China Health Care Index provides targeted exposure to this growth. Key value drivers include the expansion of China's healthcare infrastructure and increasing healthcare spending. Potential catalysts include regulatory reforms favoring the healthcare sector and advancements in medical technology within China. However, investors may want to evaluate risks such as regulatory changes, geopolitical tensions, and market volatility affecting Chinese equities. With a beta of 0.59, KURE exhibits lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
KURE Key Highlights
The fund invests at least 80% of its net assets in instruments in its underlying index.
- The underlying index is a free float adjusted market capitalization weighted index.
- The fund is designed to measure the equity market performance of Chinese companies in the healthcare sector.
- The fund is non-diversified.
- The fund has a beta of 0.59, indicating lower volatility compared to the market.
Who Are KURE's Competitors?
KURE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALTL Pacer Lunt Large Cap Alternator ETF | $46.87 | -0.42% | $107M | 50 |
| AMID Argent Mid Cap ETF | $36.49 | -0.95% | $115M | 44 |
| FEBW AllianzIM U.S. Equity Buffer20 Feb ETF | $36.09 | -0.14% | $120M | 47 |
| GSEU Goldman Sachs ActiveBeta Europe Equity ETF | $50.29 | -0.19% | $121M | 47 |
| INDS Pacer Industrial Real Estate ETF | $41.37 | -0.03% | $113M | 47 |
| TPZ Tortoise Electrification Infrastructure ETF | $21.62 | -0.18% | $127M | 70 |
| CHECU Chenghe Acquisition III Co. Units | $10.25 | +0.39% | $134M | 67 |
| ETHT ProShares - Ultra Ether ETF | $12.57 | +19.94% | $92.2M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KURE's Key Strengths?
Targeted exposure to the Chinese healthcare sector.
- Replication of a well-known index (MSCI All China Health Care Index).
- Established brand recognition as a KraneShares ETF.
- Relatively low beta of 0.59.
What Are KURE's Weaknesses?
Non-diversified nature increases risk.
- Concentration in a single country (China) exposes it to geopolitical risks.
- Dependence on the performance of the Chinese healthcare sector.
- Small market cap of $111M may limit liquidity.
What Could Drive KURE Stock Higher?
Expansion of China's healthcare infrastructure.
- Increasing demand for specialized healthcare services.
- Technological advancements in healthcare.
- Regulatory support for healthcare innovation in China.
What Are the Key Risks for KURE?
Regulatory changes in China affecting the healthcare sector.
- Geopolitical tensions between China and other countries.
- Economic slowdown in China.
- Competition from other ETFs and investment funds.
What Are the Growth Opportunities for KURE?
- Increased Healthcare Spending in China: China's healthcare expenditure is projected to grow significantly, driven by an aging population and increasing urbanization. This growth translates to greater demand for healthcare services and products, benefiting companies within the KURE index. The Chinese government's focus on improving healthcare access and quality further supports this trend. This represents a long-term growth opportunity for KURE, aligning with the overall expansion of the Chinese healthcare market.
- Technological Advancements in Healthcare: The integration of technology into healthcare, such as telemedicine, AI-driven diagnostics, and digital health platforms, is transforming the industry. Chinese healthcare companies are increasingly adopting these technologies to improve efficiency and patient outcomes. KURE's exposure to these innovative companies positions it to benefit from the technological advancements reshaping the healthcare landscape. This ongoing trend offers a sustained growth opportunity for the fund.
- Regulatory Support for Healthcare Innovation: The Chinese government is actively promoting innovation in the healthcare sector through supportive policies and funding initiatives. These measures aim to foster the development of new drugs, medical devices, and healthcare services. KURE's holdings in companies engaged in research and development activities stand to gain from this regulatory support. This ongoing government backing creates a favorable environment for growth within the Chinese healthcare sector.
- Expansion of Healthcare Infrastructure: China is investing heavily in expanding its healthcare infrastructure, including hospitals, clinics, and research facilities. This expansion creates opportunities for healthcare companies to provide equipment, supplies, and services to these new facilities. KURE's exposure to companies involved in the development and operation of healthcare infrastructure positions it to capitalize on this growth. This long-term infrastructure development supports sustained growth for the fund.
- Increasing Demand for Specialized Healthcare Services: As China's middle class grows, there is increasing demand for specialized healthcare services, such as cancer treatment, cardiovascular care, and geriatric care. Chinese healthcare companies are expanding their offerings in these areas to meet this growing demand. KURE's exposure to companies providing specialized healthcare services allows it to benefit from this trend. This ongoing shift towards specialized care creates a valuable growth opportunity for the fund.
What Are KURE's Competitive Advantages?
- Specialized focus on the Chinese healthcare sector.
- Replication of the MSCI All China Health Care Index.
- Established track record in the Chinese equity market.
- Brand recognition as a KraneShares ETF.
What Does KURE Do?
KraneShares MSCI All China Health Care Index ETF (KURE) is designed to provide investors with exposure to the healthcare sector within the Chinese equity market. The fund operates by investing at least 80% of its net assets, plus borrowings for investment purposes, in instruments that mirror its underlying index or possess similar economic characteristics. This underlying index is meticulously constructed as a free float adjusted market capitalization weighted index, adhering to the 10/40 Constraint, which is a diversification rule limiting the weight of any single component. KURE's primary objective is to closely track the equity market performance of Chinese companies operating in the healthcare sector, offering a focused investment tool for those seeking to capitalize on the growth and potential of China's healthcare industry. The fund is non-diversified, meaning it invests a larger percentage of its assets in a smaller number of issuers compared to a diversified fund.
What Products and Services Does KURE Offer?
- Invests in a portfolio of Chinese healthcare companies.
- Tracks the MSCI All China Health Care Index.
- Provides exposure to the Chinese healthcare sector.
- Offers a focused investment vehicle for Chinese equities.
- Replicates the performance of the underlying index.
- Operates as a non-diversified fund.
How Does KURE Make Money?
- Generates revenue through management fees.
- Invests in Chinese healthcare companies.
- Tracks the MSCI All China Health Care Index.
- Provides a vehicle for investors to access the Chinese healthcare market.
What Industry Does KURE Operate In?
KURE operates within the asset management industry, specifically focusing on providing access to the Chinese healthcare sector. The global asset management industry is experiencing growth, driven by increasing demand for specialized investment products. The Chinese healthcare market is expanding due to factors such as an aging population and rising income levels. KURE competes with other ETFs and investment funds offering exposure to Chinese equities and the healthcare sector. Competitors include funds with broader mandates or different weighting methodologies.
Who Are KURE's Key Customers?
- Institutional investors seeking exposure to Chinese healthcare.
- Retail investors interested in the Chinese equity market.
- Financial advisors looking for specialized investment products.
- Pension funds and endowments seeking diversification.
KURE Valuation & Market Position
With a $111M market cap, KraneShares MSCI All China Health Care Index ETF sits in the micro-cap segment of the market. Relative to its peer group, KURE's quantitative score of 44/100 is roughly in line with the peer average of 47/100.
Key Financial Metrics
Return on equity for KraneShares MSCI All China Health Care Index ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. KURE trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
KURE Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to the Chinese healthcare sector.
- Replication of a well-known index (MSCI All China Health Care Index).
- Established brand recognition as a KraneShares ETF.
- Relatively low beta of 0.59.
Bear Case
- Non-diversified nature increases risk.
- Concentration in a single country (China) exposes it to geopolitical risks.
- Dependence on the performance of the Chinese healthcare sector.
- Small market cap of $111M may limit liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
KURE Latest News
No recent news available for KURE.
KURE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KURE.
Price Targets
Wall Street price target analysis for KURE.
KURE MoonshotScore
What does this score mean?
The MoonshotScore rates KURE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
What Investors Ask About KraneShares MSCI All China Health Care Index ETF (KURE) — Financial Services
What does the AI Score mean for KURE?
KURE holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. KraneShares MSCI All China Health Care Index ETF (KURE) aims to replicate the performance of Chinese healthcare companies. The fund invests at least 80% of its assets in instruments within its …
What does KraneShares MSCI All China Health Care Index ETF do?
KraneShares MSCI All China Health Care Index ETF (KURE) is designed to track the performance of the MSCI All China Health Care Index, providing investors with targeted exposure to Chinese companies operating in the healthcare sector.
What are the main risks for KURE?
The primary risks for KURE include regulatory changes in China affecting the healthcare sector, geopolitical tensions between China and other countries, and an economic slowdown in China. As a non-diversified fund, KURE is also subject to concentration risk, meaning its performance is heavily reliant on the performance of a relatively small number of companies.
What are the key factors to evaluate for KURE?
KraneShares MSCI All China Health Care Index ETF (KURE) holds an AI score of 44/100 (low). KURE presents a focused investment opportunity in the Chinese healthcare sector, driven by the increasing demand for healthcare services in China. Not financial advice.
How frequently does KURE data refresh on this page?
KURE's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KURE's recent stock price performance?
KraneShares MSCI All China Health Care Index ETF (KURE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted exposure to the Chinese healthcare sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KURE overvalued or undervalued right now?
KraneShares MSCI All China Health Care Index ETF (KURE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KURE before investing?
Before investing in KraneShares MSCI All China Health Care Index ETF (KURE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding KURE to a portfolio?
Key strength of KraneShares MSCI All China Health Care Index ETF (KURE): Targeted exposure to the Chinese healthcare sector. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change.
- AI analysis is pending for KURE.